Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and

Trial Details

NCT ID
NCT06249191
Phase
PHASE1 / PHASE2
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Bone Marrow Aspiration and Biopsy
  • Computed Tomography
  • Cyclophosphamide
  • Doxorubicin
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • For both phases of the study, participant must be 18-75 years of age and have previously untreated high-grade B cell lymphoma (HGBCL) or diffuse la…
  • Pathology must be verified and confirmed by university pathologists at the enrolling institution and centrally (OHSU) for any biopsies read outside…
  • Stage II or higher and International Prognostic Index (IPI) score of 2-5
  • Able to comply with the study protocol and procedures, in the investigator's judgment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →